What is Hengrui Pharma's "Ascending Baiyao"?

Feigelastine, namely recombinant human granulocyte colony stimulating factor (G-CSF), is mainly used to prevent and treat leukopenia caused by tumor radiotherapy or chemotherapy, commonly known as "Shengbaiyao". Tippegolastine is a long-acting dosage form of feigelastine. By modifying G-CSF with polyethylene glycol (PEG), the metabolic time in vivo can be prolonged. Tiloprofen-Glistin injection is a second-generation long-acting G-CSF product independently developed by Hengrui Pharmaceutical for 10, and was named by the World Health Organization (WHO) for the first time. 20/kloc-0 was approved for marketing in may, 2008, and was listed in the national medical insurance catalogue in may, 2000/9, providing new treatment options for patients with neutropenia during chemotherapy for malignant tumors. Thioperfegstein's innovative structure has won many patents abroad.